Pemvidutide Body Transformation:
15.6% Weight Loss + Liver Fat Reduction — Preview with AI

What Is Pemvidutide?

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist developed by Altimmune. Unlike semaglutide (Ozempic), which targets only GLP-1 receptors, pemvidutide activates two receptors simultaneously:

• GLP-1 — Reduces appetite, slows gastric emptying, and improves blood sugar control
• Glucagon — Increases energy expenditure, promotes hepatic fat oxidation, and drives liver fat reduction

This dual mechanism gives pemvidutide a unique advantage: it delivers meaningful weight loss while specifically targeting liver fat, making it a promising candidate for patients with MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH). Clinical data also suggests better lean mass preservation compared to single-agonist GLP-1 drugs.

Pemvidutide Weight Loss Timeline

Based on MOMENTUM Phase 2b trial data, here is the expected weight loss timeline for someone starting at 220 lbs on the 2.4mg dose:

Pemvidutide vs. Ozempic vs. Mounjaro: Head-to-Head

Pemvidutide offers a differentiated profile compared to existing GLP-1 medications, with its unique combination of weight loss and liver health benefits.

Use our GLP-1 & Peptide Weight Loss Calculator to compare projected timelines for all medications based on your starting weight.

Pemvidutide Dosing Schedule

Pemvidutide is administered as a once-weekly subcutaneous injection. The dose escalation schedule from the MOMENTUM trial:

Why Pemvidutide Stands Out: Liver Health + Lean Mass

While pemvidutide's total weight loss (15.6%) is comparable to semaglutide, its dual GLP-1/glucagon mechanism provides two distinct advantages that set it apart:

• Liver fat reduction (MASH/NASH benefit): The glucagon receptor activation drives hepatic fat oxidation, significantly reducing liver fat content. This makes pemvidutide especially promising for the millions of people with metabolic dysfunction-associated steatohepatitis (MASH), a condition that can progress to cirrhosis and liver failure.
• Better lean mass preservation: Data from the MOMENTUM trial suggests that pemvidutide helps preserve metabolically active lean tissue during weight loss — meaning more of the weight you lose comes from fat rather than muscle. This is a critical concern with many weight loss medications.

Frequently Asked Questions

How much weight can you lose on pemvidutide?

In the Phase 2b MOMENTUM trial, participants on pemvidutide 2.4mg lost an average of 15.6% of their body weight over 48 weeks. This is comparable to semaglutide (Ozempic) but with the added benefit of significant liver fat reduction and better lean mass preservation.

Is pemvidutide better for liver health?

Yes. Pemvidutide has shown significant liver fat reduction in clinical trials, making it a promising candidate for patients with MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH. The glucagon receptor activation specifically drives hepatic fat oxidation, which is why pemvidutide's liver benefits exceed those of GLP-1-only drugs like semaglutide.

When will pemvidutide be available?

Pemvidutide has completed Phase 2b (MOMENTUM trial) with positive results. Altimmune is planning Phase 3 trials, but the exact timeline for FDA approval is uncertain. Until then, you can preview your potential results with BeforeAfterFit's AI visualization tool.

Does pemvidutide preserve muscle mass?

Clinical data suggests pemvidutide may preserve lean mass better than single-agonist GLP-1 medications like semaglutide. The glucagon receptor activation promotes fat oxidation while the dual mechanism helps maintain metabolically active muscle tissue during weight loss. This means a higher proportion of weight lost comes from fat rather than muscle.